Q-omics provides the consensus-scored ARHGEF10 profile across patient tissues and cancer cell-line models. ARHGEF10 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ARHGEF10 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, ARHGEF10 RNA expression shows 19,891 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, and ACC as cancer lineages where ARHGEF10 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ARHGEF10 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ARHGEF10 survival associations across molecular data types. ARHGEF10 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (10) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ARHGEF10 RNA expression–survival associations across cancer types. High ARHGEF10 expression shows unfavorable associations in LGG, LUSC, ACC, STAD and MESO, but favorable associations in KIRC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ARHGEF10 RNA expression.
This table summarizes ARHGEF10 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for ARHGEF10. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ARHGEF10 shows lower tumor expression in BLCA, THCA and LUSC and higher tumor expression in KIRC, KIRP and COAD. The KIRC box plot shows higher ARHGEF10 RNA expression in tumor versus normal tissue (log2 FC = +1.090, t-test p < 0.001).
This table shows molecular features associated with ARHGEF10 in patient tissues and cancer cell lines. In patient samples, ARHGEF10 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ARHGEF10 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and CNS.
